Global Biopharma R&D Productivity And Growth Rankings

Catenion, a biopharma-focused R&D strategy consulting firm, has analyzed the performance of the top-30 biopharma companies in 2018 and outlined major concerns for the future of innovation in drug development. 

IV1901_R-D_Productivity_389742697_1200.jpg
• Source: Shutterstock

In 2017, R&D productivity of the top-30 pharmaceutical companies had decreased for the first time since 2014, according to Catenion’s annual review of the sector. This trend continued into 2018, albeit with a lower magnitude as overall R&D productivity dropped by around 10% (vs. about 15% last year).

Yet again, the major driver is a decline in the metric that looks at pipeline value versus cumulative R&D spending...

More from Innovation

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.